-
developed by
Helsinn around 2001. In
January 2003,
Helsinn filed a
provisional patent application on palonosetron. Over the next 10 years,
Helsinn filed four...
-
developed by Novo Nordisk, and was
investigated in
phase II
clinical trials by
Helsinn Therapeutics for the
treatment of
postoperative ileus, but was discontinued...
- (netupitant/palonosetron), for
nausea and vomiting,
licensed by
Eisai Co. and
Helsinn Therapeutics.
Alecensa (alectinib), for ALK-positive non-small cell lung...
-
strong control over selling. The
original manufacturer of
nimesulide is
Helsinn Healthcare SA, Switzerland,
which acquired the
rights for the drug in 1976...
-
entered into an
agreement with the
Helsinn Group for the
exclusive distribution and
license rights to the
Helsinn Group's drug
anamorelin in Spain, Portugal...
- chemotherapy-induced
nausea and vomiting. It is
marketed and
distributed by
Helsinn Therapeutics.
Netupitant is an NK1
receptor antagonist and palonosetron...
- ZP2929 Diabetes/Obesity
Phase I ZEAL&
ELSIGLUTIDE Chemotherapy Induced diarrhea Phase II
HELSINN ZP1480(ABT-719)
Acute kidney damage Phase II Abbvie...
- appetite-enhancing and
anabolic effects which is
under development by
Helsinn Healthcare SA for the
treatment of
cancer cachexia and anorexia. Anamorelin...
-
January 2019, the
Supreme Court of the
United States decided for Teva in
Helsinn Healthcare S.A. v. Teva
Pharmaceuticals USA Inc. On May 11, 2019, Teva...
-
GenScript Glenmark Pharmaceuticals Global Pharma Tek
Grace Therapeutics Helsinn Heritage Pharmaceuticals Hovione Hudson BioPharma Immunomedics Impax Laboratories...
